Dr. Reddy''s Laboratories Ltd.

NSE: DRREDDY BSE: 500124 SECTOR: Pharmaceuticals & Drugs  106k   943   136

4385.90
-7.90 (-0.18%)
NSE: 01 Jul 03:58 PM

Price Summary

Today's High

₹ 4395

Today's Low

₹ 4290.05

52 Week High

₹ 5614.6

52 Week Low

₹ 3654

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

72999.37 Cr.

Enterprise Value

72907.57 Cr.

No. of Shares

16.64 Cr.

P/E

44.97

P/B

3.98

Face Value

₹ 5

Div. Yield

0.68 %

Book Value (TTM)

₹  1101.66

CASH

1306.3 Cr.

DEBT

1214.5 Cr.

Promoter Holding

26.72 %

EPS (TTM)

₹  97.52

Sales Growth

12.65%

ROE

13.69 %

ROCE

17.81%

Profit Growth

-25.57 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Dr. Reddy''s Laboratories Ltd.

Molflu OMEZ Nise Stamlo Clamp Econorm Razo SENQUEL-F KETOROL ATOCOR MINTOP VENUSIA Glimy Telsartan Activ

Index Presence

The company is present in 34 Indices.

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year12.65%
3 Year12.56%
5 Year5.34%

Profit Growth

1 Year-25.57%
3 Year56.82%
5 Year9.73%

ROE%

1 Year13.69%
3 Year15.13%
5 Year12.41%

ROCE %

1 Year17.81%
3 Year16.29%
5 Year13.05%

Debt/Equity

0.072

Price to Cash Flow

20.77

Interest Cover Ratio

66.4432548179872

CFO/PAT (5 Yr. Avg.)

1.27747713232125

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2022 26.72 0
Dec 2021 26.72 0
Sep 2021 26.72 0
Jun 2021 26.73 0
Mar 2021 26.74 0
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 56.822264436488% for the Past 3 years.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 66.4432548179872.
  • The company has an efficient Cash Conversion Cycle of 81.2452134870278 days.
  • Company has a healthy liquidity position with current ratio of 2.3998859724141.
  • The company has a good cash flow management; CFO/PAT stands at 1.27747713232125.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 5.25006049490999.

 Limitations

  • The company has shown a poor revenue growth of 12.5648696393281% for the Past 3 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Net Sales 3350.7 3433.5 3823.4 3479.6 3668.7
Total Expenditure 2747.8 2871.6 3075.1 2865.6 2998.8
Operating Profit 602.9 561.9 748.3 614 669.9
Other Income 81.6 186.2 118.1 63 114.7
Interest 16.9 6.5 11.1 7.7 12.7
Depreciation 210.7 197.1 206.6 205.4 205.2
Exceptional Items 0 0 0 0 0
Profit Before Tax 456.9 544.5 648.7 463.9 566.7
Tax 145.4 131.1 199.7 122.8 147
Profit After Tax 311.5 413.4 449 341.1 419.7
Adjusted EPS (Rs) 18.72 24.84 26.98 20.5 25.22

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021
Net Sales 9719.8 9359.3 10625.5 11850.4 13349.1
Total Expenditure 8041.2 8086.7 8360.9 8980.8 10212.3
Operating Profit 1678.6 1272.6 2264.6 2869.6 3136.8
Other Income 658.2 261.3 273.5 743.2 801.1
Interest 57.2 62.8 56.8 47.8 46.7
Depreciation 735.1 774.1 780.6 789.2 835
Exceptional Items 0 0 0 0 0
Profit Before Tax 1544.5 697 1700.7 2775.8 3056.2
Tax 160.4 130.1 423.4 -161.9 869.8
Net Profit 1384.1 566.9 1277.3 2937.7 2186.4
Adjusted EPS (Rs.) 83.48 34.15 76.95 176.76 131.39

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021
Equity and Liabilities
Share Capital 82.9 83 83 83.1 83.2
Total Reserves 11517.7 11724.8 12601.1 15108.8 16900.5
Borrowings 485.2 488 345.4 19.3 17.7
Other N/C liabilities 21.3 -8.5 138.7 -528.8 -186.9
Current liabilities 4258 4719.9 3079.3 4180.5 4560.3
Total Liabilities 16365.1 17007.2 16247.5 18862.9 21374.8
Assets
Net Block 4842.1 4717.3 4682.7 4433.9 5844.3
Capital WIP 540 675 400.1 384.1 877.1
Intangible WIP 0 0 0 27.7 23.7
Investments 1802.8 1953.7 1819.1 3367.1 3392.2
Loans & Advances 581.7 620.1 407 542 293.2
Other N/C Assets 4.7 2.6 5.4 1.4 0.1
Current Assets 8593.8 9038.5 8933.2 10106.7 10944.2
Total Assets 16365.1 17007.2 16247.5 18862.9 21374.8
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021
Profit from operations 1544.5 697 1700.7 2775.8 3056.2
Adjustment 648.3 964.3 958.1 681.8 273.3
Changes in Assets & Liabilities -854.1 51.3 342.1 -1141.5 632.7
Tax Paid -322.8 -174 -238.8 -476.9 -448
Operating Cash Flow 1015.9 1538.6 2762.1 1839.2 3514.2
Investing Cash Flow 1430.5 -1180.2 -546.5 -1689.2 -1453.6
Financing Cash Flow -2581.8 -304.4 -2223.1 -224.1 -794.3
Net Cash Flow -135.4 54 -7.5 -74.1 1266.3

Corporate Actions

Investors Details

PARTICULARS Mar 2021% Jun 2021% Sep 2021% Dec 2021% Mar 2022%
Promoters 26.74 26.73 26.72 26.72 26.72
g.v.prasad - - 0.71 0.71 0.75
samrajyam reddy ka... 0.67 0.67 0.67 0.67 0.67
gunupati venkatesw... 0.67 0.67 - - -
satish reddy kallam 0.54 0.54 0.61 0.61 0.61
PARTICULARS Mar 2021% Jun 2021% Sep 2021% Dec 2021% Mar 2022%
Investors 73.26 73.27 73.28 73.28 73.28
jp morgan chase ba... - - - 13.31 14.35
jp morgan chase ba... - - 13.41 - -
j p morgan chase b... - 11.23 - - -
life insurance cor... 4.91 5.27 - - -
life insurance cor... - - 3.51 4.44 -
life insurance cor... - - - - 4.44
first senter inves... 3.37 2.10 - - -
first state invest... - - 3.24 3.24 3.24
oppenheimer develo... - - 3.19 3.19 -
franklin templeton... - - 2.08 2.91 2.87
sbi mutual fund - - - - -
first state invest... - - 1.17 1.17 1.55
reliance capital t... - - - 2.08 2.57
franklin templeton... - - - 1.83 2.29
aditya birla sun l... - - 1.67 1.75 2.23
sbi-etf nifty 50 2.41 1.23 - - -
reliance capital a... - - 2.38 - -
aditya birla mutua... - - - - -
icici prudential s... 1.03 1.94 - - -
aditya birla sun l... 1.91 1.12 - - -
government of sing... 1.71 1.81 - - -
mirae asset mutual... - - - - -
franklin templeton... - - 1.75 - -
icici prudential l... 1.47 1.65 - - -
government of sing... - - - - -
nps trust-a/c hdfc... 1.41 1.50 - - -
icici prudential f... - - - - 1.31
nps trust - a/c - - - - -
uti-mastershare un... 1.24 1.20 - - -
nps trust- a/c - - - - -
mirae asset tax sa... 1.22 1.00 - - -
dsp mutual fund - - - - -
teluk kemang inves... - - 1.21 1.21 1.21
uti mutual fund - - - - -
hdfc trustee compa... - 1.02 - - -
government pension... - 1.01 - - -
iepf 0.14 0.14 0.07 0.07 0.07

Annual Reports

Ratings & Research Reports

Company Presentations

Company News

Dr.Reddy's Laboratories informs about disclosure30 Jun 2022, 12:11PM Dr. Reddy's Laboratories informs about press release28 Jun 2022, 4:57PM Dr.Reddy's Laboratories informs about press release28 Jun 2022, 2:05PM Dr. Reddy's inks settlement agreement with respect to buprenorphine and naloxone sublingual film24 Jun 2022, 5:58PM Dr. Reddy's Laboratories acquires injectable product portfolio from Eton Pharma24 Jun 2022, 4:45PM Dr.Reddy's Laboratories informs about allotment under ESOP23 Jun 2022, 4:12PM Dr.Reddy's Laboratories informs about disclosure18 Jun 2022, 2:16PM Dr. Reddy’s Laboratories informs about press release14 Jun 2022, 12:31PM Dr. Reddy's Laboratories launches Sorafenib Tablets in US market14 Jun 2022, 11:17AM Dr. Reddy's Laboratories’ arm inks exclusive global license agreement with Olema 10 Jun 2022, 9:25AM Dr. Reddy's Laboratories launches Pemetrexed for injection in US market30 May 2022, 9:36AM Dr. Reddy's Laboratories, Senores Pharmaceuticals launch Ketorolac Tromethamine Tablets25 May 2022, 10:15AM Dr. Reddy's planning to go to regulator for approvals for Sputnik Light jab as booster dose 20 May 2022, 11:52AM Dr. Reddy's Laboratories reports 83% fall in Q4 consolidated net profit19 May 2022, 6:06PM Dr Reddys Laboratories board recommends final dividend19 May 2022, 2:57PM Dr. Reddy's Lab - Quaterly Results19 May 2022, 12:57PM Dr. Reddy's Lab - Quaterly Results19 May 2022, 12:57PM Dr. Reddy's Lab - Quaterly Results19 May 2022, 12:57PM Dr. Reddy's Laboratories’ arm recalls Lansoprazole tablets in US market16 May 2022, 11:17AM Dr. Reddy’s Laboratories informs about press release11 May 2022, 9:40AM Dr. Reddy’s inks pact with HK inno.N Corporation11 May 2022, 9:22AM Dr.Reddy's Laboratories informs about press release26 Apr 2022, 10:18AM Dr. Reddy's Laboratories launches Posaconazole Delayed-Release Tablets21 Apr 2022, 9:05AM Dr Reddy's Laboratories reply to clarification sought by exchange5 Apr 2022, 2:49PM Dr. Reddy’s Laboratories launches Methylprednisolone Sodium Succinate for Injection5 Apr 2022, 2:44PM Dr. Reddy's inks pact with Novartis AG to acquire cardiovascular brand Cidmus in India2 Apr 2022, 9:47AM Dr.Reddy's Laboratories informs about cessation of CO17 Mar 2022, 3:38PM Dr. Reddy's Laboratories plans business continuity in and around Russia9 Mar 2022, 5:55PM Dr. Reddy's Laboratories enters into definitive agreement to acquire Nimbus Health GmbH25 Feb 2022, 11:09AM Dr Reddys Laboratories informs about disclosure25 Feb 2022, 10:46AM Dr. Reddy's receives EIR from USFDA for closure of inspection 21 Feb 2022, 9:26AM Dr.Reddy's Laboratories informs about press release18 Feb 2022, 5:07PM Dr. Reddy's Laboratories inks pact with Mankind Pharma16 Feb 2022, 2:26PM Dr. Reddy's enters into exclusive sales and distribution agreement with Novartis India12 Feb 2022, 9:17AM Dr. Reddy's Laboratories gets EIR from USFDA for API manufacturing plant in New York10 Feb 2022, 9:27AM Dr. Reddy's e launches authorized generic version of VASOSTRICT Vials in US Market9 Feb 2022, 6:01PM Dr. Reddy's Laboratories informs about press release7 Feb 2022, 10:00AM Dr. Reddy's gets DCGI’s nod for single-shot Sputnik Light vaccine7 Feb 2022, 9:38AM Dr Reddy's Laboratories informs about press release 3 Feb 2022, 4:27PM Dr. Reddy's enters into definitive agreement to acquire Nimbus Health GmbH 3 Feb 2022, 3:35PM Dr. Reddy's Laboratories informs about unaudited interim financial statements29 Jan 2022, 3:13PM Dr. Reddy's Laboratories informs about allotment of equity shares on exercise of ESOP28 Jan 2022, 4:36PM Dr Reddy's Laboratories reports many fold jump in Q3 consolidated net profit28 Jan 2022, 4:30PM Dr. Reddy’s Laboratories informs about press release17 Jan 2022, 4:29PM Dr. Reddy’s partners with UoH for developing cold chain logistics solutions for pharmaceutical firms7 Jan 2022, 12:45PM Dr Reddy's to launch Molflu at Rs 35 per capsule for COVID treatment 5 Jan 2022, 9:27AM Dr. Reddy's Laboratories to introduce Molnupiravir in India to treat Covid-1929 Dec 2021, 12:38PM Dr. Reddy's gets USFDA’s approval for ANDA VeraRing11 Dec 2021, 10:13AM Dr.Reddy's Laboratories informs about press release10 Dec 2021, 12:42PM Dr. Reddy's launches Venlafaxine ER Tablets in US Market10 Dec 2021, 9:13AM

Dr. Reddy''s Lab Stock Price Analysis and Quick Research Report. Is Dr. Reddy''s Lab an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Dr. Reddy''s Lab and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Its cash from the operating activity was Rs 3514.2 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Dr. Reddy''s Lab has a Debt to Equity ratio of 0.072 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Dr. Reddy''s Lab , the EPS growth was -25.6638827863766 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Dr. Reddy''s Lab has OPM of 23.4982133626986 % which is a good sign for profitability.
     
  • ROE: Dr. Reddy''s Lab have a average ROE of 13.6884414559934 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
Brief about Dr. Reddy''s Lab

X